What Is Continuous Glucose Monitoring?

Continuous glucose monitoring is a form of biomedical monitoring in which a wearable sensor estimates glucose concentration automatically at short intervals, typically every one to five minutes, throughout the day and night. Rather than sampling capillary blood with a fingerstick, the sensor measures glucose in the interstitial fluid of the subcutaneous tissue and transmits readings wirelessly to a receiver, insulin pump, or smartphone. The resulting trace shows direction and rate of change, information a series of isolated blood measurements cannot provide.

The technology combines electrochemical biosensing, low-power embedded electronics, signal processing, and biocompatible materials engineering. Research supported by the National Institute of Diabetes and Digestive and Kidney Diseases contributed to the first system cleared by the U.S. Food and Drug Administration in 1999, and successive generations have reduced sensor size, extended wear time, and removed the requirement for routine user calibration.

Sensing Chemistry and Sensor Design

Nearly all commercial systems use an amperometric enzyme electrode. Glucose oxidase immobilized on a working electrode catalyzes the oxidation of glucose, and the resulting current, mediated either by hydrogen peroxide detection or by a redox mediator, is proportional to glucose concentration. A thin filament electrode is inserted a few millimeters into subcutaneous tissue and held in place by an adhesive patch carrying the transmitter, while fully implantable variants using fluorescence-based sensing operate for months at a time. Membrane design is where much of the engineering effort goes, since the outer layer must limit glucose flux to keep the electrode within its linear range, exclude interfering species such as acetaminophen and ascorbate, and resist the protein adsorption and foreign body response that degrade sensitivity over a wear period. A review of minimally invasive electrochemical glucose sensors traces how these material choices set the achievable lifetime.

Calibration, Lag, and Accuracy

Interstitial glucose tracks blood glucose closely but not instantaneously. Diffusion across the capillary wall introduces a physiological delay of several minutes, and sensor filtering adds more, so readings lag during rapid excursions such as the rise after a meal or the fall after insulin. Manufacturers compensate with predictive filtering and with factory calibration derived from tightly controlled electrode manufacturing, which has largely replaced twice-daily fingerstick calibration. Accuracy is reported as mean absolute relative difference against a laboratory reference, and regulatory clearance of integrated systems depends on meeting accuracy thresholds across the full glycemic range, including hypoglycemia, where errors carry the greatest clinical consequence.

Data Interpretation and Closed-Loop Control

A continuous trace supports metrics that a fingerstick cannot, above all time in range, the proportion of a day spent between defined glucose thresholds, along with glycemic variability and the frequency and duration of nocturnal lows. These metrics have entered clinical guidelines alongside hemoglobin A1c. The same data stream is the input to automated insulin delivery, where a control algorithm adjusts basal insulin from the pump in response to sensor readings and predicted trajectory. A survey of continuous glucose monitoring in pediatric practice describes how alarm design, data-sharing with caregivers, and remote review have changed management as much as the sensing hardware itself.

Applications

Continuous glucose monitoring has applications in a range of fields, including:

• Type 1 and type 2 diabetes management
• Automated insulin delivery and artificial pancreas systems
• Gestational diabetes and neonatal glucose surveillance
• Inpatient and perioperative glycemic control
• Clinical trials requiring dense metabolic endpoints
• Consumer metabolic health and exercise physiology